Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 343 participants.

Also called NCT01917656

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 343 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01917656
Other papers using this trial's data
  • Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial Diabetes, obesity & metabolism, 2016-10 DOI, PubMed 27376711, PMC5095865 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Algeria, India, Israel, Lebanon, Malaysia, South Africa, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01917656. Randomized; no masking; primary purpose treatment. Start 2014-01-09 (actual); primary completion 2014-09-01 (actual). Results posted on 2015-10-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
Acronym
LIRA-Ramadan™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
metformin
Intervention (Drug)
sulphonylurea
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01917656
Content hash
d19279654eafcc9e0c3ad7c8c73f433845325b6f99873c4a156339fbadd43a1a